S&P 500   4,337.44
DOW   34,006.88
QQQ   359.61
3 Blue Chip Safe Havens to Shield Your Portfolio
Save $300 on MarketBeat All Access (Ad)
Is Jet Blue's Descent Into Penny Stock Territory an Opportunity?
Are Gene Therapy Stocks The Market's Next Big Winners?
The single greatest medical breakthrough of all time? (Ad)
3 Stocks That Flourish In The Fall
Buy The World’s Largest IT Infrastructure Provider For Under $20
The single greatest medical breakthrough of all time? (Ad)
2 Must-Have Silicon Companies That Don't Make Microchips
Small Caps That Have Priced In A Hard Landing For Big Upside
S&P 500   4,337.44
DOW   34,006.88
QQQ   359.61
3 Blue Chip Safe Havens to Shield Your Portfolio
Save $300 on MarketBeat All Access (Ad)
Is Jet Blue's Descent Into Penny Stock Territory an Opportunity?
Are Gene Therapy Stocks The Market's Next Big Winners?
The single greatest medical breakthrough of all time? (Ad)
3 Stocks That Flourish In The Fall
Buy The World’s Largest IT Infrastructure Provider For Under $20
The single greatest medical breakthrough of all time? (Ad)
2 Must-Have Silicon Companies That Don't Make Microchips
Small Caps That Have Priced In A Hard Landing For Big Upside
S&P 500   4,337.44
DOW   34,006.88
QQQ   359.61
3 Blue Chip Safe Havens to Shield Your Portfolio
Save $300 on MarketBeat All Access (Ad)
Is Jet Blue's Descent Into Penny Stock Territory an Opportunity?
Are Gene Therapy Stocks The Market's Next Big Winners?
The single greatest medical breakthrough of all time? (Ad)
3 Stocks That Flourish In The Fall
Buy The World’s Largest IT Infrastructure Provider For Under $20
The single greatest medical breakthrough of all time? (Ad)
2 Must-Have Silicon Companies That Don't Make Microchips
Small Caps That Have Priced In A Hard Landing For Big Upside
S&P 500   4,337.44
DOW   34,006.88
QQQ   359.61
3 Blue Chip Safe Havens to Shield Your Portfolio
Save $300 on MarketBeat All Access (Ad)
Is Jet Blue's Descent Into Penny Stock Territory an Opportunity?
Are Gene Therapy Stocks The Market's Next Big Winners?
The single greatest medical breakthrough of all time? (Ad)
3 Stocks That Flourish In The Fall
Buy The World’s Largest IT Infrastructure Provider For Under $20
The single greatest medical breakthrough of all time? (Ad)
2 Must-Have Silicon Companies That Don't Make Microchips
Small Caps That Have Priced In A Hard Landing For Big Upside

Agios Pharmaceuticals (AGIO) Stock Forecast, Price & News

$24.41
-0.12 (-0.49%)
(As of 09/25/2023 ET)
Compare
Today's Range
$24.06
$24.79
50-Day Range
$24.41
$28.17
52-Week Range
$21.07
$31.87
Volume
276,552 shs
Average Volume
454,602 shs
Market Capitalization
$1.36 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$36.00

Agios Pharmaceuticals MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.50 Rating Score
Upside/​Downside
47.5% Upside
$36.00 Price Target
Short Interest
Bearish
11.04% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.53
Upright™ Environmental Score
News Sentiment
1.61mentions of Agios Pharmaceuticals in the last 14 days
Based on 2 Articles This Week
Insider Trading
Selling Shares
$1.65 M Sold Last Quarter
Proj. Earnings Growth
Growing
From ($6.29) to ($4.70) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.07 out of 5 stars

Medical Sector

514th out of 962 stocks

Pharmaceutical Preparations Industry

228th out of 449 stocks


AGIO stock logo

About Agios Pharmaceuticals (NASDAQ:AGIO) Stock

Agios Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of medicines in the field of cellular metabolism. The company develops PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias; and AG-946, a PK activator for treating lower-risk myelodysplastic syndrome and hemolytic anemias. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.

AGIO Price History

AGIO Stock News Headlines

Nektar Therapeutics (NKTR) Gets a Sell from Bank of America Securities
This is the #1 Stock to Buy for the AI Tidal Wave
Marc Chaikin warned people about NVDA before its 2023 bull run - now he’s naming his next pick or the AI tidal wave. Learn more here.
J.P. Morgan Reaffirms Their Hold Rating on Sana Biotechnology (SANA)
Agios Pharmaceuticals Inc (8AP.BE)
This is the #1 Stock to Buy for the AI Tidal Wave
Marc Chaikin warned people about NVDA before its 2023 bull run - now he’s naming his next pick or the AI tidal wave. Learn more here.
Here's what Wall Street expects from Agios Pharmaceuticals's earnings
See More Headlines
Receive AGIO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Agios Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

AGIO Company Calendar

Last Earnings
8/03/2023
Today
9/25/2023
Next Earnings (Estimated)
11/02/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:AGIO
Fax
N/A
Employees
389
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$36.00
High Stock Price Forecast
$41.00
Low Stock Price Forecast
$32.00
Forecasted Upside/Downside
+48.5%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
4 Analysts

Profitability

Net Income
$-231,800,000.00
Net Margins
-1,042.56%
Pretax Margin
-1,042.56%

Debt

Sales & Book Value

Annual Sales
$14.24 million
Book Value
$20.03 per share

Miscellaneous

Free Float
53,376,000
Market Cap
$1.35 billion
Optionable
Optionable
Beta
0.95
7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed Investors Cover

As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.

Get This Free Report

Key Executives

  • Mr. Brian M. Goff M.B.A. (Age 54)
    CEO & Director
    Comp: $1.23M
  • Ms. Cecilia Jones (Age 48)
    Chief Financial Officer
    Comp: $403.36k
  • Mr. James William Burns (Age 45)
    Corp. Sec. & Chief Legal Officer
    Comp: $660.33k
  • Dr. Sarah Gheuens M.D. (Age 43)
    Ph.D., Chief Medical Officer and Head of R&D
    Comp: $769.2k
  • Dr. Lewis Clayton Cantley Ph.D. (Age 74)
    Co-Founder & Member of Scientific Advisory Board
  • Dr. Tak Wah Mak D.Sc. (Age 77)
    FRSC, Ph.D., Co-Founder & Member of Scientific Advisory Board
  • Dr. Craig B. Thompson M.D. (Age 70)
    Co-Founder & Chairman of Scientific Advisory Board
  • Dr. Shin-San Su Ph.D. (Age 67)
    Co-Founder & Member of Scientific Advisory Board
  • Mr. T. J. Washburn Jr. (Age 42)
    Principal Accounting Officer
  • Dr. Clive Patience Ph.D. (Age 59)
    Chief Technical Operations Officer













AGIO Stock - Frequently Asked Questions

Should I buy or sell Agios Pharmaceuticals stock right now?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Agios Pharmaceuticals in the last twelve months. There are currently 2 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" AGIO shares.
View AGIO analyst ratings
or view top-rated stocks.

What is Agios Pharmaceuticals' stock price forecast for 2023?

4 brokerages have issued 1 year price targets for Agios Pharmaceuticals' stock. Their AGIO share price forecasts range from $32.00 to $41.00. On average, they predict the company's share price to reach $36.00 in the next twelve months. This suggests a possible upside of 48.5% from the stock's current price.
View analysts price targets for AGIO
or view top-rated stocks among Wall Street analysts.

How have AGIO shares performed in 2023?

Agios Pharmaceuticals' stock was trading at $28.08 on January 1st, 2023. Since then, AGIO shares have decreased by 13.6% and is now trading at $24.25.
View the best growth stocks for 2023 here
.

When is Agios Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, November 2nd 2023.
View our AGIO earnings forecast
.

How were Agios Pharmaceuticals' earnings last quarter?

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) posted its earnings results on Thursday, August, 3rd. The biopharmaceutical company reported ($1.51) earnings per share for the quarter, beating analysts' consensus estimates of ($1.60) by $0.09. The biopharmaceutical company earned $6.70 million during the quarter, compared to analysts' expectations of $6.46 million. Agios Pharmaceuticals had a negative net margin of 1,042.56% and a negative trailing twelve-month return on equity of 20.24%. Agios Pharmaceuticals's revenue was up 20.1% on a year-over-year basis. During the same quarter last year, the firm posted ($1.68) EPS.

What ETFs hold Agios Pharmaceuticals' stock?
What is Jackie Fouse's approval rating as Agios Pharmaceuticals' CEO?

11 employees have rated Agios Pharmaceuticals Chief Executive Officer Jackie Fouse on Glassdoor.com. Jackie Fouse has an approval rating of 100% among the company's employees. This puts Jackie Fouse in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Agios Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Agios Pharmaceuticals investors own include Gilead Sciences (GILD), Micron Technology (MU), Alibaba Group (BABA), bluebird bio (BLUE), Pfizer (PFE), Vertex Pharmaceuticals (VRTX), NVIDIA (NVDA), Tesla (TSLA) and Netflix (NFLX).

What is Agios Pharmaceuticals' stock symbol?

Agios Pharmaceuticals trades on the NASDAQ under the ticker symbol "AGIO."

Who are Agios Pharmaceuticals' major shareholders?

Agios Pharmaceuticals' stock is owned by a number of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (8.48%), Rock Springs Capital Management LP (4.82%), State Street Corp (4.63%), JPMorgan Chase & Co. (4.47%), Dimensional Fund Advisors LP (4.06%) and ArrowMark Colorado Holdings LLC (2.82%). Insiders that own company stock include Brian Goff, Carman Alenson, Cecilia Jones, Christopher Bowden, Darrin Miles, David P Schenkein, Jacqualyn A Fouse, James William Burns, Kaye I Foster-Cheek and Theodore James Jr Washburn.
View institutional ownership trends
.

How do I buy shares of Agios Pharmaceuticals?

Shares of AGIO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Agios Pharmaceuticals' stock price today?

One share of AGIO stock can currently be purchased for approximately $24.25.

How much money does Agios Pharmaceuticals make?

Agios Pharmaceuticals (NASDAQ:AGIO) has a market capitalization of $1.35 billion and generates $14.24 million in revenue each year. The biopharmaceutical company earns $-231,800,000.00 in net income (profit) each year or ($3.80) on an earnings per share basis.

How many employees does Agios Pharmaceuticals have?

The company employs 389 workers across the globe.

How can I contact Agios Pharmaceuticals?

Agios Pharmaceuticals' mailing address is 88 SIDNEY STREET, CAMBRIDGE MA, 02139. The official website for the company is www.agios.com. The biopharmaceutical company can be reached via phone at (617) 649-8600 or via email at investors@agios.com.

This page (NASDAQ:AGIO) was last updated on 9/26/2023 by MarketBeat.com Staff

My Account -